Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.66 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.66 |
| ▸ | RXRA | P19793 | 9/20 | 0.57 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678676 | 0.91 | NR1H2 (0.66) | NR1H2NR1H3RXRAADAMTS4MMP13 | |
| SCHEMBL1679334 | 0.90 | NR1H2 (0.65) | NR1H2NR1H3RXRAADAMTS4MMP13 | |
| SCHEMBL1678343 | 0.87 | NR1H2 (0.72) | NR1H2NR1H3RXRAADAMTS4MMP13 | |
| SCHEMBL1678473 | 0.86 | NR1H2 (0.63) | NR1H2NR1H3RXRAADAMTS4MMP13 | |
| SCHEMBL1678322 | 0.85 | NR1H2 (0.79) | NR1H2NR1H3RXRAPTGER4SRD5A2 | |
| SCHEMBL1679052 | 0.85 | NR1H2 (0.62) | NR1H2NR1H3RXRAPTGS2 | |
| SCHEMBL1679624 | 0.85 | NR1H2 (0.62) | NR1H2NR1H3RXRAADAMTS4MMP13 | |
| SCHEMBL1678724 | 0.85 | NR1H2 (0.59) | NR1H2NR1H3RXRAADAMTS4MMP13 | |
| SCHEMBL1679505 | 0.84 | NR1H2 (0.61) | NR1H2NR1H3RXRAADAMTS4MMP13 | |
| SCHEMBL1679472 | 0.83 | NR1H2 (0.62) | NR1H2NR1H3RXRAADAMTS4MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | NR1H2 1/4885NR1H3 2/4885RXRA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.